Posted by Michael Wonder on 07 Mar 2025
Lazertinib approved for use in combination with amivantamab for the treatment of adults with non-small cell lung cancer
6 March 2025 - The MHRA has today approved lazertinib (Lazcluze) for adults with non-small cell lung cancer that has spread to other parts of the body and has undergone specific changes in a gene called epidermal growth factor receptor.
It is to be used in combination with an approved cancer medicine called amivantamab.
